A Phase 1 Study of MOR209/ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1 Study of MOR209/ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs APVO-414 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Aptevo Therapeutics; Emergent Product Development Seattle
  • Most Recent Events

    • 31 Aug 2017 According to an Aptevo Therapeutics media release, from amended protocol two cohorts of continuous infusion of MOR209/ES414 have completed the dosing.
    • 31 Aug 2017 Preliminary results presented in the Aptevo Therapeutics media release.
    • 31 Aug 2017 According to an Aptevo Therapeutics media release, the company has terminated its collaboration with MorphoSys AG for MOR209/ES414 drug and intend to continue the development of the drug MOR209/ES414 (under the name APVO414) through the completion of Stage 1 of this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top